Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 127.67B +98.4% |
| Revenue (ttm) | 51.58B +4.1% |
| Net Income | 2.10B |
| EPS | 1.79 |
| Shares Out | n/a |
| PE Ratio | 60.70 |
| Forward PE | 12.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 770,113 |
| Open | 10,900 |
| Previous Close | 11,020 |
| Day's Range | 10,870 - 11,100 |
| 52-Week Range | 5,606 - 11,350 |
| Beta | 0.88 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Humana agrees not to reference Teva's Israel ties at US drug trial
Health insurer Humana has agreed not to refer to drugmaker Teva as an Israeli company at an upcoming U.S. drug price-fixing trial, after the drugmaker said public views on the Gaza war could unfairly...
TEVA Maintained by Barclays -- Price Target Raised to $42.00
TEVA Maintained by Barclays -- Price Target Raised to $42.00
Teva (TEVA) Q2 2026 Earnings Call Transcript
Key innovative brands now generate over $1B quarterly revenue.
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
SUPN vs. TEVA: Which Stock Is the Better Value Option?
Teva seeks to keep Israel ties from jury, cites Gaza war
Teva Pharmaceuticals has asked a U.S. judge to prevent insurer Humana from telling jurors it is an Israeli company at a major drug price-fixing trial, arguing that strong public views over the Gaza ...
Why Teva Pharmaceutical Stock Surged This Week
Teva posted its Q2 results this week, reporting an earnings miss even though sales beat expectations. The company's forward guidance didn't deliver big surprises, but it looked solid enough.
Teva Pharmaceutical Industries Q2 Earnings Call Highlights
Teva Pharmaceutical Industries NYSE: TEVA reported second-quarter 2026 revenue of approximately $4.1 billion, down 1% from a year earlier in U.S. dollars, as lower sales from generic Revlimid were lar...
TEVA SWOT Analysis: Financial Struggles Amidst Strategic Shifts Revealed in 10-Q Filing
TEVA SWOT Analysis: Financial Struggles Amidst Strategic Shifts Revealed in 10-Q Filing
TEVA Looks 71.0% Overvalued on GF Value⢠as Insider Selling Persists
TEVA Looks 71.0% Overvalued on GF Value⢠as Insider Selling Persists
Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 9.6% Rally? GF Value Says Overvalued
Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 9.6% Rally? GF Value Says Overvalued
Stocks to Watch Recap: Ford, Caterpillar, Teva, Starbucks
Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations
Teva CEO on Q2 earnings: 'Good growth across the whole portfolio'
Richard Francis, President and CEO of Teva Pharmaceuticals, joins 'Squawk on the Street' to discuss Q2 results, drug pipeline, generics business, and more.
Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views
Teva's bullish guidance overshadowed mixed second-quarter results.
Watch CNBC's full interview with Teva Pharmaceuticals CEO Richard Francis
Richard Francis, President and CEO of Teva Pharmaceuticals, joins 'Squawk on the Street' to discuss Q2 results, drug pipeline, generics business and more.
Teva Pharmaceutical Industries Q2 2026 Disappoints: EPS 93.8% Below Estimates
Significant Miss. Teva Pharmaceutical Industries Limited (NYSE:TEVA) stumbled badly in Q2 2026, reporting non-GAAP diluted earnings of $0.02 per share again... The post Teva Pharmaceutical Industries ...
TEVA Looks 56.0% Overvalued on GF Value⢠as Insider Selling Persists
TEVA Looks 56.0% Overvalued on GF Value⢠as Insider Selling Persists
Is Teva Pharmaceutical Industries Ltd (TEVA) Facing Challenges After Q2 Earnings Miss? GAAP ...
Is Teva Pharmaceutical Industries Ltd (TEVA) Facing Challenges After Q2 Earnings Miss? GAAP Loss Per Share at $0.49, GF Score: 54/100
Teva Pharmaceutical Industries Earnings Call Transcript: Q2 2026
Q2 2026 saw strong growth in innovative products, offsetting generics decline, with raised guidance for AUSTEDO, AJOVY, and UZEDY. Free cash flow rose 31%, and the company advanced its pipeline and biosimilars portfolio while maintaining disciplined capital allocation.
Teva Pharmaceutical Industries Slides: Q2 2026
Teva Pharmaceutical Industries has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Teva Pharmaceutical Industries Earnings release: Q2 2026
Teva Pharmaceutical Industries released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Teva Pharmaceutical Industries Quarterly report: Q2 2026
Teva Pharmaceutical Industries has published its Q2 2026 quarterly earnings report on July 29, 2026.
Teva Pharmaceutical Industries Releases Q2 2026 Financial Results
Teva Pharmaceutical Industries Limited reported a sharp earnings miss for the second quarter of 2026, posting non-GAAP diluted earnings of $0. The post Teva Pharmaceutical Industries Releases Q2 2026 ...
UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in ...
Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a recor...